Acadia Pharma to Announce Q4 Earnings on February 25
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy ACAD?
Source: seekingalpha
- Earnings Announcement Date: Acadia Pharma is set to announce its Q4 2023 earnings on February 25 after market close, with market participants keenly awaiting the results, which may impact stock performance.
- Earnings Expectations: The consensus EPS estimate stands at $0.14, indicating a year-over-year growth expectation that reflects investor optimism regarding the company's profitability.
- Revenue Estimate Fluctuations: Revenue is projected at $292.59 million, representing a 12.7% increase year-over-year; however, in the last three months, revenue estimates have seen three upward revisions and five downward revisions, indicating market uncertainty about future performance.
- Analyst Rating Changes: Over the past three months, EPS estimates have experienced two upward revisions and four downward revisions, suggesting a divergence in analyst opinions regarding Acadia Pharma's earnings outlook, which could influence investor confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACAD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACAD
Wall Street analysts forecast ACAD stock price to rise
12 Analyst Rating
7 Buy
5 Hold
0 Sell
Moderate Buy
Current: 24.560
Low
23.00
Averages
31.17
High
40.00
Current: 24.560
Low
23.00
Averages
31.17
High
40.00
About ACAD
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. It develops and commercializes medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of product candidates and research programs that are designed to address significant unmet medical needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and ACP-711. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. Its early-stage research programs and product candidates include ACP-211, ACP-2591, ACP-271, and Antisense Oligonucleotide (ASO) Programs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Neuren and Acadia Request Re-examination for Rett Syndrome Drug
- Re-examination Request: Acadia Pharmaceuticals will request a re-examination of the CHMP's opinion on trofinetide, aimed at treating Rett syndrome in patients aged two and older, reflecting ongoing commitment to drug approval efforts.
- Market Authorization: Trofinetide is already approved in the U.S., Canada, and Israel, representing the first and only treatment for Rett syndrome, highlighting its potential and significance in the global market.
- Executive Commentary: Acadia CEO Catherine Owen Adams expressed disappointment over the CHMP's refusal but remains optimistic about the drug's meaningful benefits for Rett syndrome patients, emphasizing positive feedback from patients and clinicians.
- Market Reaction: ACAD shares fell 7.13% to $22.81 during regular trading on Monday, yet gained 0.04% in after-hours trading, indicating cautious optimism in the market regarding the drug's future potential.
See More
Aardvark Pauses PWS Trial, Shares Plunge 53%
- Trial Pause Reason: Aardvark Therapeutics announced a voluntary pause of its ARD-101 trial for Prader-Willi Syndrome due to cardiac observations in a healthy volunteer study, with data release now expected to be delayed until Q3 2026, potentially impacting the company's future R&D trajectory.
- Severe Market Reaction: Following the trial pause announcement, Aardvark's shares plunged 53% in after-hours trading, reflecting extreme investor concern over the company's outlook, which may lead to financing challenges and diminished market confidence.
- Competitor Dynamics: In contrast, Soleno Therapeutics' VYKAT XR has become the first FDA-approved treatment for hyperphagia in Prader-Willi Syndrome, despite facing short-selling pressure and safety concerns from Scorpion Capital, highlighting the intense competition in the market.
- Industry-Wide Challenges: Against the backdrop of Aardvark's trial pause, Acadia Pharmaceuticals also halted development of its intranasal Carbetocin, indicating that the challenges and risks associated with successful R&D in the Prader-Willi Syndrome treatment space are increasing, which could affect the overall investment attractiveness of the sector.
See More
ACADIA Pharmaceuticals Reports Strong Q4 2025 Earnings with $1 Billion Annual Revenue
- Significant Revenue Growth: ACADIA Pharmaceuticals reported adjusted total revenues of $298 million in Q4 2025, a 16% increase year-over-year, with annual revenues surpassing $1 billion for the first time at $1.08 billion, indicating strong commercial execution in the NUPLAZID and DAYBUE brands.
- Optimistic NUPLAZID Sales Outlook: The company expects NUPLAZID net sales to reach between $760 million and $790 million in 2026, representing a growth of 10% to 14% over 2025, laying a solid foundation for achieving blockbuster status with $1 billion in sales by 2028.
- DAYBUE Market Expansion: DAYBUE's net sales were reported at $110 million for Q4 and $391 million for the year, successfully expanding into the U.S. community physician market, with 76% of new prescriptions originating from community-based physicians, reflecting the company's success in broadening its market reach.
- R&D and Financial Outlook: Projected R&D expenses for 2026 are between $385 million and $410 million, with SG&A expenses expected to be between $660 million and $700 million, reflecting ongoing investments in foundational capabilities and field force expansion to support future growth potential.
See More
ACADIA (ACAD) Q4 2025 Earnings Call Transcript
See More
Acadia Pharma to Announce Q4 Earnings on February 25
- Earnings Announcement Date: Acadia Pharma is set to announce its Q4 2023 earnings on February 25 after market close, with market participants keenly awaiting the results, which may impact stock performance.
- Earnings Expectations: The consensus EPS estimate stands at $0.14, indicating a year-over-year growth expectation that reflects investor optimism regarding the company's profitability.
- Revenue Estimate Fluctuations: Revenue is projected at $292.59 million, representing a 12.7% increase year-over-year; however, in the last three months, revenue estimates have seen three upward revisions and five downward revisions, indicating market uncertainty about future performance.
- Analyst Rating Changes: Over the past three months, EPS estimates have experienced two upward revisions and four downward revisions, suggesting a divergence in analyst opinions regarding Acadia Pharma's earnings outlook, which could influence investor confidence.
See More
Baker Bros. Advisors Increases Stake in Kymera Therapeutics
- Stake Increase: Baker Bros. Advisors reported a purchase of 2,005,813 shares of Kymera Therapeutics in its February 17, 2026 SEC filing, representing an estimated trade value of $135.45 million, indicating strong confidence in the company.
- Market Value Growth: The fund's quarter-end position in Kymera Therapeutics increased by $297.15 million due to this purchase, reflecting the dual impact of trading activity and share price appreciation, further solidifying its market position.
- Stock Performance: As of February 17, 2026, Kymera's shares were priced at $84.84, marking a 130% increase over the past year, significantly outperforming the S&P 500 by 118.13 percentage points, showcasing its robust performance in the biotech sector.
- R&D Outlook: With approximately $1.6 billion in cash at the beginning of 2026, Kymera supports its leading oral immunology pipeline, which is expected to drive sustained growth for the company in the coming years.
See More
Neuren and Acadia Request Re-examination for Rett Syndrome Drug
- Re-examination Request: Acadia Pharmaceuticals will request a re-examination of the CHMP's opinion on trofinetide, aimed at treating Rett syndrome in patients aged two and older, reflecting ongoing commitment to drug approval efforts.
- Market Authorization: Trofinetide is already approved in the U.S., Canada, and Israel, representing the first and only treatment for Rett syndrome, highlighting its potential and significance in the global market.
- Executive Commentary: Acadia CEO Catherine Owen Adams expressed disappointment over the CHMP's refusal but remains optimistic about the drug's meaningful benefits for Rett syndrome patients, emphasizing positive feedback from patients and clinicians.
- Market Reaction: ACAD shares fell 7.13% to $22.81 during regular trading on Monday, yet gained 0.04% in after-hours trading, indicating cautious optimism in the market regarding the drug's future potential.
See More
Aardvark Pauses PWS Trial, Shares Plunge 53%
- Trial Pause Reason: Aardvark Therapeutics announced a voluntary pause of its ARD-101 trial for Prader-Willi Syndrome due to cardiac observations in a healthy volunteer study, with data release now expected to be delayed until Q3 2026, potentially impacting the company's future R&D trajectory.
- Severe Market Reaction: Following the trial pause announcement, Aardvark's shares plunged 53% in after-hours trading, reflecting extreme investor concern over the company's outlook, which may lead to financing challenges and diminished market confidence.
- Competitor Dynamics: In contrast, Soleno Therapeutics' VYKAT XR has become the first FDA-approved treatment for hyperphagia in Prader-Willi Syndrome, despite facing short-selling pressure and safety concerns from Scorpion Capital, highlighting the intense competition in the market.
- Industry-Wide Challenges: Against the backdrop of Aardvark's trial pause, Acadia Pharmaceuticals also halted development of its intranasal Carbetocin, indicating that the challenges and risks associated with successful R&D in the Prader-Willi Syndrome treatment space are increasing, which could affect the overall investment attractiveness of the sector.
See More
ACADIA Pharmaceuticals Reports Strong Q4 2025 Earnings with $1 Billion Annual Revenue
- Significant Revenue Growth: ACADIA Pharmaceuticals reported adjusted total revenues of $298 million in Q4 2025, a 16% increase year-over-year, with annual revenues surpassing $1 billion for the first time at $1.08 billion, indicating strong commercial execution in the NUPLAZID and DAYBUE brands.
- Optimistic NUPLAZID Sales Outlook: The company expects NUPLAZID net sales to reach between $760 million and $790 million in 2026, representing a growth of 10% to 14% over 2025, laying a solid foundation for achieving blockbuster status with $1 billion in sales by 2028.
- DAYBUE Market Expansion: DAYBUE's net sales were reported at $110 million for Q4 and $391 million for the year, successfully expanding into the U.S. community physician market, with 76% of new prescriptions originating from community-based physicians, reflecting the company's success in broadening its market reach.
- R&D and Financial Outlook: Projected R&D expenses for 2026 are between $385 million and $410 million, with SG&A expenses expected to be between $660 million and $700 million, reflecting ongoing investments in foundational capabilities and field force expansion to support future growth potential.
See More
ACADIA (ACAD) Q4 2025 Earnings Call Transcript
See More
Acadia Pharma to Announce Q4 Earnings on February 25
- Earnings Announcement Date: Acadia Pharma is set to announce its Q4 2023 earnings on February 25 after market close, with market participants keenly awaiting the results, which may impact stock performance.
- Earnings Expectations: The consensus EPS estimate stands at $0.14, indicating a year-over-year growth expectation that reflects investor optimism regarding the company's profitability.
- Revenue Estimate Fluctuations: Revenue is projected at $292.59 million, representing a 12.7% increase year-over-year; however, in the last three months, revenue estimates have seen three upward revisions and five downward revisions, indicating market uncertainty about future performance.
- Analyst Rating Changes: Over the past three months, EPS estimates have experienced two upward revisions and four downward revisions, suggesting a divergence in analyst opinions regarding Acadia Pharma's earnings outlook, which could influence investor confidence.
See More
Baker Bros. Advisors Increases Stake in Kymera Therapeutics
- Stake Increase: Baker Bros. Advisors reported a purchase of 2,005,813 shares of Kymera Therapeutics in its February 17, 2026 SEC filing, representing an estimated trade value of $135.45 million, indicating strong confidence in the company.
- Market Value Growth: The fund's quarter-end position in Kymera Therapeutics increased by $297.15 million due to this purchase, reflecting the dual impact of trading activity and share price appreciation, further solidifying its market position.
- Stock Performance: As of February 17, 2026, Kymera's shares were priced at $84.84, marking a 130% increase over the past year, significantly outperforming the S&P 500 by 118.13 percentage points, showcasing its robust performance in the biotech sector.
- R&D Outlook: With approximately $1.6 billion in cash at the beginning of 2026, Kymera supports its leading oral immunology pipeline, which is expected to drive sustained growth for the company in the coming years.
See More
